MedTrace Logo

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

NCT04462419 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2025-09-10

No results posted yet for this study

Summary

This phase I trial studies the ability and amount of fluciclovine positron emission tomography (PET) imaging needed to recognize tumors that have come back (recurrence) after brain injury from radiation therapy (radionecrosis) in patients with intracranial disease that has spread to other places in the body (metastatic). F-18 fluciclovine is a radiotracer that works by accumulating in tumor cells, making it easier to detect tumors. The results of this study may also help investigators understand all the ways that F-18 fluciclovine may affect patients.

Conditions

  • Metastatic Intracranial Malignant Neoplasm
  • Recurrent Intracranial Neoplasm

Interventions

RADIATION

Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Positron Emission Tomography

Undergo PET-MRI imaging

OTHER

Fluciclovine F18

Given IV

Sponsors & Collaborators

  • Blue Earth Diagnostics

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Daniel M. Trifiletti, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-18
Primary Completion
2023-12-13
Completion
2024-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04462419 on ClinicalTrials.gov